Director subscriptions/PDMR dealing

Tissue Regenix Group plc

Director subscriptions/PDMR dealing

Leeds, 5 June 2020 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix", the "Company" or the "Group"), the regenerative medical devices company, announces that following today's release of its annual results, certain members of the Board have conditionally subscribed for a total of £620,000 (the "Subscription"). The Subscription was highlighted in the Company's recent equity fundraising, further details of which were first announced on 21 May 2020 (the "Fundraise").

The Subscription will result in the issue and allotment of a total of 248,000,000 new ordinary shares in the Company and is being carried out at the same issue price of 0.25p and on identical terms as those of the Fundraise.

Director subscriptions

The following Directors have conditionally subscribed for shares in the Company in the amounts set out in the table below:

The participation by Jonathan Glenn, Randeep Grewal, Alan Miller and Gareth Jones in the Fundraising constitutes a related party transaction for the purposes of the AIM Rules. The Independent Director, being Shervanthi Homer-Vanniasinkam, having consulted with the Company's nominated adviser, Stifel, consider that the terms of the related party transaction are fair and reasonable insofar as shareholders are concerned.

General meeting and importance of the vote

The Subscription and wider Fundraise is conditional on, amongst other things, the passing of the Placing Resolutions to be proposed at a general meeting to be held at the offices of Squire Patton Boggs (UK) LLP, 6 Wellington Place, Leeds at 12 p.m. on 9 June 2020 (the "General Meeting").

Unless otherwise defined, capitalised words used in this notice have the meanings given to them in the Proposed Equity Fundraise regulatory announcement, as released on 21 May 2020.

For more Information:

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL^®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies^®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.